Stoke Therapeutics (NASDAQ:STOK) vs. Renovaro (NASDAQ:RENB) Critical Survey

Stoke Therapeutics (NASDAQ:STOK) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.

Profitability

This table compares Stoke Therapeutics and Renovaro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-629.90%	-54.45%	-40.77%
Renovaro	N/A	-61.84%	-48.07%

Institutional and Insider Ownership

71.4% of Renovaro shares are held by institutional investors. 11.3% of Stoke Therapeutics shares are held by insiders. Comparatively, 21.7% of Renovaro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Stoke Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

Valuation and Earnings

This table compares Stoke Therapeutics and Renovaro”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$190.91 million	3.12	-$104.70 million	$0.79	13.80
Renovaro	N/A	N/A	-$80.65 million	($0.77)	-0.37

Renovaro has lower revenue, but higher earnings than Stoke Therapeutics. Renovaro is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Stoke Therapeutics and Renovaro, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	0	0	5	2	3.29
Renovaro	0	0	0	0	0.00

Stoke Therapeutics currently has a consensus price target of $23.20, indicating a potential upside of 112.84%. Given Stoke Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Stoke Therapeutics is more favorable than Renovaro.

Summary

Stoke Therapeutics beats Renovaro on 9 of the 14 factors compared between the two stocks.

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

About Renovaro

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.